DIWALI SPECIAL

25% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim Offer →
logo
Market statusData NSENot investment advice
THYROCARE TECH

THYROCARE TECH Latest Share Price (THYROCARE)

₹498.25
10.25+2.10%
Overall Score74/100
Day range487
₹498.25
500
52-week343
₹498.25
1,610
Above low+45.5%
Below high69.1%
Range position12%
Open488.00
Prev Close488.00
Bid498.23100
Ask498.28100

TODAY IN ONE LINE

THYROCARE rose 2.1% on light volume, outperforming Nifty's -0.6% move.

With a market cap of ₹7,926.43 Cr., it trades at a P/E of 54.97. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.

Volume222.1K−69%vs 20D avg
Price Band20
Lower Band365
Upper Band547.4
Tick Size0.05
Daily Volatility2.47%
Annualised Vol47.19%
Market Cap₹7,926.43 Cr.
Promoter51.02%
Face Value₹10
Fwd P/E39.03
PEG1.47
EV/EBITDA20.57
P/S10.28
ROA17.69%
Beta0.44
Div Payout159.63%
THE STOCK SCORE
Overall Score74/100
Updated 14 Nov

How good is this company?

Overall performance across 5 key dimensions.

Each card tappable → shows formula + inputs
FLAGS & NEWS

THYROCARE TECH flags & news 

Key strengths, potential risks, and recent updates.

✅ 9 green flags🚩 4 red flags

Green Flags

  • ●Earnings GrowthEPS (TTM) grew by a solid 116.3% YoY
  • ●High Capital EfficiencyROCE of 28.3% indicating pricing power
  • ●Strong Return on EquityHealthy ROE of 26.5%
  • ●Healthy Operating MarginsOPM is structurally strong at 27.5%
  • ●High Promoter HoldingPromoters hold 51.0% skin-in-the-game
  • ●Steady Dividend YieldReliable 1.41% dividend yield
  • ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
  • ●FII AccumulationFII holding increased by 3.93% QoQ
  • ●Positive Free Cash FlowFCF has been positive for 3 consecutive years

Red Flags

  • ●Expensive ValuationTrading at a high P/E ratio of 53.1x
  • ●Promoter SellingPromoter holding decreased by 9.90% QoQ
  • ●Rising Receivables vs SalesReceivables grew 58.4% outpacing sales growth of 20.2%
  • ●Promoter Pledging DetectedPledge activity recorded on 2026-08-18

Latest THYROCARE TECH News

THE CHANGELOG

What changed recently?

Recent events, corporate actions, and announcements.

No recent changes found for this period.
🔒Prime: full history + alerts on this stock
Valuation

THYROCARE TECH valuation: P/E, P/B and sector benchmarks.

Twelve years of multiples investors have paid for THYROCARE TECH, framed against the sector median so the premium or discount is obvious at a glance.

THYROCARE TECH trades at a P/E of 54.97× and P/B of 14.32×.

Key MetricsMarket + reported · 13 Nov 2026Consolidated

Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.

Valuation

Valuation

Market Cap
₹7,926.43 Cr.
P/E Ratio
54.97
P/B Ratio
14.32
EPS
₹1
Profitability

Profitability

ROE
26.54%
ROCE
28.32%
Net Margin
19.67%
Op Margin
27.46%
Growth

Growth

EPS YoY
116.3%
Revenue YoY
19.7%
Qtr Sales
12.83%
Qtr Profit
-70.35%
Financial Health

Financial Health

Debt / Equity
—
Book Value
₹36.82
Div Yield
1.41%
Promoter Holding
51.02%
Technicals

THYROCARE TECH technical analysis: indicators, pivots and CPR.

Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for THYROCARE TECH — derived from the latest tape, not yesterday's close.

THYROCARE TECH last traded at ₹498.25 with an intraday range of ₹487.1–₹500.2 — latest indicator, pivot and CPR signals below.

Last updated: 16 November 2026, 4:08 pm IST

Pivot points

Standard pivot — most widely referenced.

Pivot levels · Classic

Last: ₹498.25
LevelPrice (₹)Distance% Δ
R4529.47+31.22+6.27%
R3516.37+18.12+3.64%
R2508.28+10.03+2.01%
R1503.27+5.02+1.01%
PIVOT495.18-3.07-0.62%
CURRENT498.25——
S1490.17-8.08-1.62%
S2482.08-16.17-3.24%
S3477.07-21.18-4.25%
S4463.97-34.28-6.88%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: 493.65P: 495.18TC: 496.72
R1
R2
R3
R4
indicator
LTP: 498.25
PDH: 492.85
PDL: 482.80
● Market Sentiment

THYROCARE is trading Above CPR, indicating Bullishness

● CPR Width

CPR is Wider, suggesting unlikely for trending moves

● Opening Range

Day's range: ₹487.9–₹493

● Price Position

Trading Above opening range, showing Bullishness

Financials

THYROCARE TECH financials: P&L, balance sheet, cash flow, ratios.

Reported annual and quarterly results for THYROCARE TECH — consolidated or standalone — with margins, YoY growth and key ratios inline.

THYROCARE TECH reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹7,926.43 Cr. and reported EPS of ₹1.00.

iTap any row for a plain-English meaning▲▼Change vs a year ago — green means the move is healthy for that line, red means it isn’tDerivedCalculated by us, not reported directly
Mobile view
Latest vs previous year
MetricMar 2026May 2026
Revenue from Operations829
829
▲ 0.0%
Sales Growth YoY %Derived20.61%
—
Other Income17
17
▲ 0.0%
Total Income846
846
▲ 0.0%
220
220
▲ 0.0%
Gross ProfitDerived609
609
▲ 0.0%
Gross Margin %Derived73.52%
73.52%
347
347
▲ 0.0%
EBITDA (Operating Profit)Derived262
262
▲ 0.0%
OPM %Derived31.61%
31.61%
55
55
▲ 0.0%
Profit Before Tax (PBT)211
211
▲ 0.0%
50
50
▲ 0.0%
Effective Tax %Derived23.66%
23.66%
Total Profit for Period163
163
▲ 0.0%
Less: Non-controlling Interests-0
-0
▲ 0.0%
Net Profit (Owner's PAT)Derived163
163
▲ 0.0%
Net Profit Margin %Derived19.67%
19.67%
PAT Growth YoY %Derived78.17%
—
Earnings Per Share (EPS ₹)10.24
10.24
▲ 0.0%
Diluted Shares Outstanding (Cr)16
16
▲ 0.0%
Share of Profit from Associates/JVs1
1
▲ 0.0%
Other Comprehensive Income (Net of Tax)0
0
▲ 0.0%
Total Expenses (incl. D&A & Interest)635
635
▲ 0.0%
Material Cost % of RevenueDerived26.38%
26.38%
Employee Cost % of RevenueDerived16.65%
16.65%
Other Cost % of RevenueDerived25.25%
25.25%
Interest Coverage (x)Derived72.66x
72.66x
Sales CAGR · 3Y
+6.4%
Sales CAGR · 5Y
+7.7%
PAT CAGR · 3Y
+21.2%
PAT CAGR · 5Y
+18.2%
all values in ₹ Cr unless marked % / x / ₹ · fiscal-period end shown · reported figures via Stockezee financials API · annual results may be audited; quarterly results may be unaudited or limited-review
Segment Analysis

THYROCARE TECH segment analysis : revenue and profit mix.

Disclosed business segments at THYROCARE TECH with their share of revenue and profit, switchable between consolidated and standalone reporting.

THYROCARE TECH discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.

Segment-wise Financial Analysis

Thesis

The Bull, Bear, and Flip case for THYROCARE TECH.

Our AI distills the core fundamental drivers supporting THYROCARE TECH, the risks that threaten it, and the quantitative conditions that could weaken the thesis.

bull case

What you're getting.

No strengths or opportunities on record.

bear case

Key Risks.

No weaknesses or threats on record.

flip conditions

Flip Conditions.

  • Valuation risk. a P/E above 71 would leave less room for earnings disappointment.

  • Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.

  • Return-quality risk. ROE below 22% would indicate weaker capital compounding.

  • Income thesis breaks if the dividend is cut or yield falls below 0.70%.

Shareholding

THYROCARE TECH shareholding pattern: promoters, FII, DII and public.

Quarter-on-quarter ownership shifts in THYROCARE TECH — who is buying, who is exiting, and which institutions hold the largest positions.

Shareholding Pattern

Annual • Sep 2026

Public13.70%↑0.98%
FII9.37%↑3.93%
DII25.92%↑5.00%
Promoters51.02%↓9.90%

Ownership Distribution

Retail & Public
13.70%
Foreign Institutions
9.37%
Domestic Institutions
25.92%
Promoters
51.02%

Category Trends

Foreign Institutions Breakdown
Total Holding: 9.37%
Net Change: +3.93%
Category Total9.37%
Total Holding9.37%
Net Change+3.93%
Not Fully Disclosed

⚠️Partial Disclosure Notice

Individual institutions below total 0.00%, but category aggregate is 9.37%. Some institutions may not be disclosed by the company as per regulatory requirements.

Institution Name
Trend (Last 6)
Holding %
QoQ Change
YoY ChangePeriod
Abu Dhabi Investment Council - (Noosa)
0.00%
0.00%
0.00%
Sep 2026
Pictet - Indian Equities
0.00%
0.00%
0.00%
Sep 2026
NEW HORIZON OPPORTUNITIES MASTER FUND
0.00%
0.00%
0.00%
Sep 2026
AI Mehwar Commercial Investments LLC (Noosa)
0.00%
0.00%
0.00%
Sep 2026
FIL INVESTMENTS(MAURITIUS)LTD
0.00%
0.00%
0.00%
Sep 2026
Nomura India Investment Fund Mother Fund
0.00%
0.00%
0.00%
Sep 2026
THELEME INDIA MASTER FUND LIMITED
0.00%
0.00%
0.00%
Sep 2026
Arisaig Asia Fund Limited
0.00%
0.00%
0.00%
Sep 2026
Arisaig Asia Consumer Fund Limited
0.00%
0.00%
0.00%
Sep 2026
Nalanda India Equity Fund Limited
0.00%
0.00%
0.00%
Sep 2026
Al Mehwar Commercial Investments L.L.C. - (Noosa)
0.00%
0.00%
0.00%
Sep 2026
Fundsmith Emerging Equities Trust Plc
0.00%
0.00%
0.00%
Sep 2026
Peers

THYROCARE TECH peer comparison — same-sector benchmarks.

Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — THYROCARE TECH is highlighted for quick read-across.

Quick Compare

Largest by Market Cap
DR. LAL PATH LABS
₹33,301.21 Cr
Best Profit Growth
KRSNAA DIAGNOSTICS
48.55 %
Highest Dividend Yield
THYROCARE TECH
1.41 %
09 · Chart Patterns

THYROCARE TECH chart patterns: breakouts, tops and bottoms.

Auto-detected classical chart patterns for THYROCARE TECH — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.

Delivery Conviction

THYROCARE TECH delivery volume — last 20 sessions of conviction.

Daily traded volume and delivery percentage for THYROCARE TECH over 20 sessions — the gap between intraday flipping and genuine accumulation.

Latest session delivery in THYROCARE TECH stood at 56.5% of traded volume, against a 20-day average of 51.0%.

Avg Delivery (20D)51%+5.5 ppt latest vs avg
Highest Delivery78.6%on 12 Nov
Avg Volume (20D)7.25 L20-day run-rate
Conviction Trend↑ Strengthening+5.5 ppt latest read
Volume & Delivery · last 20 sessions
Exchange Filings & Investor Updates

THYROCARE TECH announcements: results, concalls, ratings, M&A.

Filings THYROCARE TECH sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.

THYROCARE TECH files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 157 documents below.

  1. 06 Nov 2026Resignation of Director/KMP/SMPView PDF

    Resignation of Director/KMP/SMP

    Thyrocare Technologies Limited has informed the Exchange about Resignation of Director/KMP/SMP

  2. 06 Nov 2026ESOP/ESOS/ESPSView PDF

    ESOP/ESOS/ESPS

    Thyrocare Technologies Limited has informed the Exchange regarding Allotment of 194289 Equity Shares pursuant to the Thyrocare Employee Stock Option…

  3. 06 Nov 2026ResignationView PDF

    Resignation

    Thyrocare Technologies Limited has informed the Exchange regarding Resignation of Dr. Preet Kaur as Chief Scientific Officer of the company w.e.f.…

  4. 02 Nov 2026Analysts/Institutional Investor Meet/Con. Call UpdatesView PDF

    Analysts/Institutional Investor Meet/Con. Call Updates

    Thyrocare Technologies Limited has informed the Exchange about Transcript

  5. 30 Oct 2026AgreementsView PDF

    Agreements

    Thyrocare Technologies Limited has informed the Exchange about Execution of Share Purchase Agreement in relation to the sale of the Company s entire…

Corporate Actions

THYROCARE TECH dividend history, splits and bonus issues.

Every dividend, stock split and bonus issue THYROCARE TECH has declared, sequenced by announce and record date.

THYROCARE TECH corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.

Insider Activity

THYROCARE TECH insider trading: promoter and management activity.

Promoter, director and designated-employee transactions in THYROCARE TECH as reported to SEBI — buying and selling signals from the people who know the business best.

THYROCARE TECH insider activity below tracks 44 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).

InsiderCategoryTxn DateActionQuantityValue (₹)Price
Priyanka Jagnani JainInsider30 Mar 2026buy+2.5 K₹8.76 L₹350.50
Geetanjali Satish ShahaneInsider30 Mar 2026buy+1.0 K₹3.58 L₹358.20
Priyanka Jagnani JainInsider30 Mar 2026buy+2.5 K₹8.76 L₹350.50
Geetanjali Satish ShahaneInsider30 Mar 2026buy+1.0 K₹3.58 L₹358.20
Geetanjali Satish ShahaneInsider30 Mar 2026buy+1.0 K₹3.58 L₹358.20
Priyanka Jagnani JainInsider30 Mar 2026buy+2.5 K₹8.76 L₹350.50
Geetanjali Satish ShahaneInsider30 Mar 2026buy+1.0 K₹3.58 L₹358.20
Priyanka Jagnani JainInsider30 Mar 2026buy+2.5 K₹8.76 L₹350.50
Geetanjali Satish ShahaneInsider30 Mar 2026buy+1.0 K₹3.58 L₹358.20
Priyanka Jagnani JainInsider30 Mar 2026buy+2.5 K₹8.76 L₹350.50
About the Company

About THYROCARE TECH: business, sector, key facts.

What THYROCARE TECH does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.

THYROCARE TECH operates in the Healthcare Service Provider industry under the Healthcare sector, listed as NSE: THYROCARE, BSE: 539871.

THYROCARE
Healthcare

THYROCARE TECH

NSE · THYROCARE·BSE · 539871·www.thyrocare.com

Thyrocare Technologies Limited is a prominent Indian healthcare company specializing in diagnostic testing services. Its primary business revolves around providing a wide range of medical tests to patients, hospitals, and other laboratories across the country. The company’s focus is on early detection and proactive management of various health conditions, contributing to preventative healthcare.

Thyrocare's services encompass a broad spectrum of diagnostic tests, targeting numerous health areas. These include thyroid disorders (the company's namesake), growth and metabolic issues, autoimmune diseases, diabetes, anemia, cardiovascular health concerns, infertility, and a variety of infectious diseases. This comprehensive approach allows for a holistic assessment of patient health, aiding in early diagnosis and subsequent treatment.

The company operates under a three-segment structure: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment forms the core of Thyrocare's business, encompassing the vast majority of its testing portfolio. The Imaging Services segment likely includes diagnostic imaging procedures, although the provided text does not offer specifics. The "Others" segment appears to encompass ancillary products and services, such as the sale of glucometers and glucostrips under the Sugarscan brand, as well as consumables and radiopharmaceutical products.

A significant aspect of Thyrocare's strategy is its Aarogyam brand. This brand offers a suite of wellness and preventive healthcare tests, catering to individuals focused on proactive health maintenance. These profiles of tests are designed to identify potential health risks early on, allowing for timely intervention and improved health outcomes. By offering a range of tests, from specialized diagnostic tests to comprehensive wellness packages, Thyrocare aims to cater to a wide patient base and various healthcare needs.

In summary, Thyrocare Technologies Limited is a vertically integrated diagnostics company focused on providing a comprehensive suite of testing services aimed at early disease detection and preventive healthcare. Its diverse offerings, including specialized tests, wellness packages, and ancillary products, position it as a major player in the Indian healthcare market. The company's success hinges on its ability to deliver accurate, timely, and cost-effective diagnostic services across a broad range of health conditions.

company facts
Employees1,906
SectorHealthcare
HeadquartersNavi Mumbai, India
Market Cap₹7,926.43 Cr.
Listed OnNSE
leadership22 on record
Dr. Dhaval Shah
Non-Executive Non-Independent Director
Dr. Harshil Vora
Non-Executive Independent Director
Dr. Indumati Gopinathan
Non-Executive Independent Director
Dr. Prapti Gilada
Non-Executive Independent Director
Dr. Ramesh Kinha
Chief Operating Officer
Mr. Aditya Shinde
Vice President
Mr. Alok Jagnani
Non-Executive Non-Independent Director
Mr. Anandh Sundar
Non-Executive Independent Director
Mr. Brijesh Kumar
Compliance Officer, Company Secretary
Mr. Brijesh Kumar
Company Secretary & Compliance Officer
Mr. Dharmil Sheth
Non-Executive Non-Independent Director
Mr. Hardik Dedhia
Non-Executive Non-Independent Director
§ ∞ · Plainly Answered

Questions investors ask about THYROCARE TECH (THYROCARE).

Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.

01What is the current share price of THYROCARE TECH (THYROCARE)?

The current share price of THYROCARE TECH (THYROCARE) is ₹498.25. Today, the stock has gained by ₹10.25 (2.1%), trading in a range of ₹487.10 to ₹500.20. The stock opened at ₹488.00 with a trading volume of 2,22,106 shares.

02Is THYROCARE TECH stock a good investment for long-term?

THYROCARE TECH can be considered for long-term investment based on several factors. The company has a market capitalization of ₹7,926.43 Cr., P/E ratio of 54.97, ROE of 26.54%, and ROCE of 28.32%. The dividend yield stands at 1.41%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

03What is the 52-week high and low price of THYROCARE TECH stock?

The 52-week high price of THYROCARE TECH (THYROCARE) is ₹1,610.00, while the 52-week low is ₹342.55. Currently trading at ₹498.25, the stock is 45.45% above its 52-week low and 69.05% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

04Should I buy THYROCARE TECH stock at the current price?

Whether to buy THYROCARE TECH stock at ₹498.25 depends on multiple factors. The stock is currently trading with a P/E ratio of 54.97 and P/B ratio of 14.32. Today's performance shows a gain of 2.1%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

05What is the dividend yield of THYROCARE TECH and when is the next dividend?

THYROCARE TECH offers a dividend yield of 1.41%, which means for every ₹100 invested at the current price of ₹498.25, you can expect to receive approximately ₹1.41 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

06What are the key financial ratios and metrics of THYROCARE TECH?

THYROCARE TECH's key financial metrics include: P/E Ratio: 54.97, P/B Ratio: 14.32, ROE: 26.54%, ROCE: 28.32%, Dividend Yield: 1.41%, EPS: ₹1.00, Book Value: ₹36.82, and Debt-to-Equity: 0. The company's market cap stands at ₹7,926.43 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.

07How is THYROCARE TECH stock performing today in the market?

THYROCARE TECH stock opened at ₹488.00 and is currently trading at ₹498.25, showing a gain of ₹10.25 (2.1%). The intraday high is ₹500.20 and low is ₹487.10. The trading volume stands at 2,22,106 shares, indicating moderate market participation today.

08What is the P/E ratio of THYROCARE TECH and what does it indicate?

THYROCARE TECH has a Price-to-Earnings (P/E) ratio of 54.97, which means investors are willing to pay 54.97 for every ₹1 of earnings. With an EPS of ₹1.00, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.

Disclaimer

The data, ratios and commentary about THYROCARE TECH (THYROCARE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.